RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH - RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a ...
Read more